Audentes Therapeutics, Inc.
http://www.audentestx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Audentes Therapeutics, Inc.
Audentes Set To Resume XLMTM Trial As US Hold Lifts
Trial of high-need gene therapy set to restart following the deaths of several participants and the lifting of a clinical hold imposed by the US FDA last year.
Stockwatch: Innovative Therapies 2020 – A Commercial Odyssey
The development and commercialization of cell and gene therapies during a pandemic, with regulators and payers demanding more data on effect duration and safety, has resulted in headwinds. Added to manufacturing and clinical trial recruitment issues, investors’ patience has been strained.
AnGes Takes Gene Editor Emendo Into Fold For $258m
Japanese firm sees broad promise in already affiliated US bioventure’s platform tech that will help it become a more global player in genetic medicine.
Third Death In Audentes’ XLMTM Gene Therapy Trial
Astellas subsidiary says it “remains committed” to on-hold program in high-need disease despite fatal events.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
-
Drug Delivery
- Macromolecule
-
Biotechnology
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- Cardiogen Sciences, Inc.